S
SIGA Technologies
Specializes in developing therapeutic solutions for some of the most lethal pathogens – smallpox
At a glance
- Status
- Listed
- Founded
- 1995
- Headquarters
- New York City, United States
- Listing
- IPO 1997
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
National Institutes of Health
US National Institute of Allergy and Infectious Diseases
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
9 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about SIGA Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SIGA Technologies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.